Key Prognostic Factors Create a Composite Risk Score to Stratify Patients into High- and Low-Treatment Benefit Groups: A Multicenter, Retrospective Data Analysis of 84 Metastatic Colorectal Cancer Patients Treated with Regorafenib as Part of the CORRECT and CONSIGN Trials

INTRODUCTION: In further-line mCRC treatment, median progression-free survival (PFS) is rather short, and many patients do not benefit from any antitumor treatment and should therefore be treated according to best-supportive care. A risk score based on standard laboratory values using markers of tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Zöhrlaut, Linda Katharina, Karthaus, Meinolf, Vehling-Kaiser, Ursula, von Kunhardt, Lukas, Stintzing, Sebastian, Heinemann, Volker, von Einem, Jobst C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614442/
https://www.ncbi.nlm.nih.gov/pubmed/37607525
http://dx.doi.org/10.1159/000531268

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614442/
https://www.ncbi.nlm.nih.gov/pubmed/37607525
http://dx.doi.org/10.1159/000531268

Ejemplares similares